Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J I Weitz

Showing results (81-90 of 136) with videos related to

Pageof 14
Sort By:
Blood|May 1, 1997
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in ratsJ M Muir, J Hirsh, J I Weitz, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2016
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTHJ H Levy, W Ageno, N C Chan, et al.
Circulation|February 7, 2001
Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)studyJ W Eikelboom, S S Anand, S R Mehta, et al.
Journal of Thrombosis and Haemostasis : JTH|October 5, 2017
Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrationsI H Jaffer, N Chan, R Roberts, et al.
Nuclear Medicine and Biology|June 1, 2000
Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in bloodH Dougan, D M Lyster, C V Vo, et al.
Thrombosis and Haemostasis|May 4, 1992
Measurement of markers of activated coagulation in antithrombin III deficient subjectsC Demers, J S Ginsberg, P Henderson, et al.
Lancet (London, England)|June 20, 2000
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisJ W Eikelboom, S S Anand, K Malmberg, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2014
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagentsB J Dale, J S Ginsberg, M Johnston, et al.
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding modelP Klement, S Carlsson, J Rak, et al.
The Journal of Clinical Investigation|November 1, 1988
Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogenJ I Weitz, M K Cruickshank, B Thong, et al.
Pageof 14

Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
Blood|May 1, 1997
A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in ratsJ M Muir, J Hirsh, J I Weitz, et al.
Journal of Thrombosis and Haemostasis : JTH|February 26, 2016
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTHJ H Levy, W Ageno, N C Chan, et al.
Circulation|February 7, 2001
Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)studyJ W Eikelboom, S S Anand, S R Mehta, et al.
Journal of Thrombosis and Haemostasis : JTH|October 5, 2017
Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrationsI H Jaffer, N Chan, R Roberts, et al.
Nuclear Medicine and Biology|June 1, 2000
Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in bloodH Dougan, D M Lyster, C V Vo, et al.
Thrombosis and Haemostasis|May 4, 1992
Measurement of markers of activated coagulation in antithrombin III deficient subjectsC Demers, J S Ginsberg, P Henderson, et al.
Lancet (London, England)|June 20, 2000
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisJ W Eikelboom, S S Anand, K Malmberg, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2014
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagentsB J Dale, J S Ginsberg, M Johnston, et al.
Journal of Thrombosis and Haemostasis : JTH|July 23, 2003
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding modelP Klement, S Carlsson, J Rak, et al.
The Journal of Clinical Investigation|November 1, 1988
Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogenJ I Weitz, M K Cruickshank, B Thong, et al.
Pageof 14